Vaccines Market to Grow by USD 193.7 Billion (2025-2029), Increased Funding for Development and New Launches Boost the Market, Report on How AI is Driving Market Transformation - Technavio

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- Report with the AI impact on market trends - The global vaccines market size is estimated to grow by USD 193.7 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of almost 23%  during the forecast period. Increased funding for vaccine development and new vaccine launches is driving market growth, with a trend towards development of nanoparticle vaccines. However, high cost of vaccine research, development, and manufacturing  poses a challenge. Key market players include Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BrightPath Biotherapeutics Co., Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GSK Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson Inc., Merck KGaA, Mitsubishi Chemical Group Corp., Novavax Inc., Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd., and Valneva SE.

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Market Driver

The vaccines market is experiencing explosive growth trends due to the urgent need to combat life-threatening infectious diseases such as Dengue fever, Influenza, Tuberculosis, Malaria, Zika virus, HIV, and TB. Immunization programs are the primary drivers of this market, with billions of people relying on vaccines to prevent diseases and save lives. Vaccine development is a complex process involving trial and error, high development costs, and collaboration between immunology experts, healthcare systems, and international organizations. Key diseases in focus include Dengue, Hepatitis A-Hepatitis B, Malaria, and HIV. Vaccines come in various forms such as conjugate, recombinant, inactivated & subunit, live attenuated, and toxoid vaccines, each with unique advantages for different disease indications. Affluent nations are leading the demand for shots, but least developed countries face challenges in vaccine distribution and affordability. The competitive pipeline is filled with emerging players, mergers, and manufacturing expansions. In the post-pandemic period, the focus is on market expansion and addressing diseases like Cervical cancer with vaccines like Cervavac. Government surveillance and press releases on vaccine trials and vaccine introductions continue to shape the market. The demand for vaccines against diseases like Diphtheria, Tetanus, Pertussis, and Measles remains high. The competitive landscape includes players focusing on diseases like Ebola and birth cohort vaccinations for Diarrhea and Pneumonia. The market is expected to continue its growth in the coming years, with a focus on addressing the needs of pediatric and adult populations for various viral and bacterial diseases. 

Infectious diseases pose a significant health risk to people globally. Researchers are working diligently to create new vaccines and enhance the effectiveness of existing ones against specific diseases. Historically, vaccines have been produced using protein subunits and killed pathogens. However, these vaccines carry the risk of regaining pathogenicity in immunocompromised individuals. To address this concern, the development of efficient vaccines in conjunction with suitable delivery systems is crucial to achieve the desired immune response against targeted diseases. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

• The vaccines market faces several challenges in immunization programs due to the high development cost and complexities in creating effective shots for various life-threatening infectious diseases like Dengue fever, Influenza, Tuberculosis, Malaria, Zika virus, HIV, and TB. Immunology, therapeutic vaccines, conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, and toxoid vaccines are all part of the competitive pipeline. Billions of people worldwide rely on vaccines for their health, with diseases like Diphtheria, Tetanus, and Pertussis being common targets. However, the market faces hurdles such as trial and error in vaccine development, distribution challenges, and ceasings of immunizations in least developed countries. The post-pandemic period is expected to see explosive growth trends, with demand for shots against viral diseases like Hepatitis A-Hepatitis B, and bacterial diseases like Malaria, rotavirus, herpes zoster, meningococcal disease, pneumococcal disease, and diseases with high mortality rates like Ebola. Governments, international organizations, and healthcare systems play crucial roles in vaccine introduction and distribution. Mergers, manufacturing, sales, and government surveillance are key areas of focus. The market expansion includes vaccines for age groups from pediatric to adults, and for diseases like cervical cancer (Cervavac) and HIV. The competitive landscape includes emerging players, high costs, and vaccine dose affordability. Vaccine doses for diseases like measles, pneumonia, and diarrhea are essential for reducing deaths and improving global health.
• Vaccines have significantly contributed to combating various infectious and life-threatening diseases, such as smallpox's successful eradication in several countries. However, the development of new vaccines is essential due to the ongoing need for disease prevention. The Coalition for Epidemic Preparedness Innovations (CEPI) aims to develop vaccines for epidemic infectious diseases. According to CEPI's research, creating a single vaccine for an epidemic disease from preclinical trials to Phase IIa costs between USD31-USD68 million, without accounting for potential clinical trial failures. The high investment required for vaccine development and manufacturing hinders progress.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview 

This vaccines market report extensively covers market segmentation by  

1. Type 
• 1.1 Human vaccine
• 1.2 Animal vaccine
2. End-user 
• 2.1 Hospitals
• 2.2 Clinics
3. Geography 
• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)

1.1 Human vaccine-  In the global vaccines market, human vaccines represent a significant segment, encompassing a diverse range of products designed to prevent infectious diseases and promote public health. These vaccines function by stimulating the immune system's response to specific pathogens, providing immunity against various diseases. Human vaccines can be classified into several types based on their composition, mechanism of action, and target population. One type is the inactivated or killed vaccine, which contains non-infectious pathogens, such as the inactivated polio vaccine (IPV) and influenza vaccine. These vaccines are generally safer for individuals with weakened immune systems but may necessitate multiple doses for adequate immunity. Another type is the live attenuated vaccine, which includes weakened forms of the pathogen, such as the measles, mumps, and rubella (MMR) vaccine and oral polio vaccine (OPV). Live attenuated vaccines typically confer long-lasting immunity with a single dose but may pose a risk to individuals with compromised immune systems. Subunit vaccines consist of specific proteins or antigenic fragments derived from the pathogen, like the hepatitis B vaccine and human papillomavirus (HPV) vaccine. Safer than live vaccines, subunit vaccines often require adjuvants or multiple doses to boost their immunogenicity. Additionally, conjugate vaccines combine a weak antigen with a carrier protein to enhance the immune response, particularly in young children. Examples include the pneumococcal conjugate vaccine and Haemophilus influenzae type b (Hib) vaccine. Human vaccines play a vital role in preventing infectious diseases and reducing the disease burden worldwide. Continued research and development, along with improvements in vaccine delivery and access, will drive the growth of the human vaccine segment in the global vaccines market.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

The Vaccines market is witnessing explosive growth trends due to the increasing burden of diseases such as TB (Tuberculosis), which claimed over 1.5 million deaths in 2019. The development of vaccines like Live Attenuated and Toxoid varieties continues through trial and error processes. Vaccine introduction, led by organizations like PAHO, aims to strengthen healthcare systems and reduce mortality rates. The ceasing of immunizations in some regions due to various reasons poses challenges to the market. The pandemic situation has highlighted the importance of vaccines, with the Government of India recently introducing Cervavac for cervical cancer. Immunization policies and government foundations are collaborating to ensure vaccine availability and affordability. The competitive pipeline includes new vaccines like the Dengue tetavalent vaccine and Hepatitis A-Hepatitis B vaccine. The market is witnessing a shift towards Live Attenuated, Parenteral, and Oral vaccines to improve accessibility and efficacy. A recent press release announced the successful completion of trials for a new Pneumococcal vaccine supply agreement. Government surveillance and ongoing research continue to drive innovation in the vaccines market.

Market Research Overview

The vaccines market is witnessing explosive growth trends due to the increasing demand for shots against life-threatening infectious diseases such as Dengue fever, Influenza, Tuberculosis, Malaria, Zika virus, HIV, and TB (Tuberculosis). Immunization programs are the primary drivers of this market, with billions of people relying on vaccines to protect their health. Vaccine development is a complex process involving immunology, therapeutic vaccines, conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and more. The high development cost of vaccines is a significant challenge, but the potential to save lives and reduce mortality rates makes it a worthwhile investment. The competitive pipeline includes emerging players, mergers, manufacturing, sales, and trial and error. Diseases such as Diphtheria, Tetanus, Pertussis, and Measles continue to be major indications, with a focus on vaccines for viral diseases like Hepatitis A-Hepatitis B, and bacterial diseases like Malaria, Rotavirus, Herpes zoster, Meningococcal disease, and Pneumococcal disease. The market expansion includes vaccines for age groups ranging from pediatric to adults, with a focus on diseases like Cervical cancer (Cervavac) and Ebola regimens. International organizations play a crucial role in vaccine distribution, particularly in least developed countries, where immunization rates are lower and the ceasing of immunizations can lead to disease outbreaks. The post-pandemic period is expected to see continued demand for vaccines, with a focus on global supply, hospitals, and government surveillance. A recent press release announced the development of a Malaria vaccine, adding to the growing demand for vaccines to combat various diseases.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Type
• Human Vaccine
• Animal Vaccine
• End-user
• Hospitals
• Clinics
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio